Liquid Biopsy Has Emerged as a New Hope For Cancer Patients

Liquid Biopsy Has Emerged as a New Hope For Cancer Patients

Cancer is one of the leading causes of death in the world and the mortality rate due to cancer is going to increase further in the future. Despite the developments in medical science over the course of the past few decades, the biggest challenge that oncology is facing is the development of non-invasive methods to detect and monitor tumors. Tissue biopsy is one of the methods, which is invasive in nature, costly, painful, and risky for the patient. However, another option, liquid biopsy, has emerged as a new hope for the cancer patients to reduce the health risks involved in diagnosis and treatment.

Liquid biopsy is a non-invasive method which detects epidermal growth factor receptor (EGFR) gene mutations through fragments of DNA shed by tumours into the bloodstream. This method is used for the early detection of cancer and patient monitoring, as well to monitor the patient’s response to the treatment. An alternative to surgical biopsies, liquid biopsy will help the doctors to choose the suitable treatment for a patient at the right time. Earlier, the research in the liquid biopsy method revolved mostly around lung, breast, and prostate cancers, but currently the research on this technology is expected to have an immense impact over a wider cancer spectrum.

The non-invasiveness and convenience this method provides to the patients is one of the major reasons for the rapid growth in its popularity. The healthcare industry is also counting on the potential exhibited by liquid biopsy which can help in the detection of disease progression and treatment resistance at an early stage i.e., before the cancer triggers the clinical symptoms. This method also makes it possible to detect different types of genetic mutation in a cancer tumor which is not possible with tissue biopsy. Hence, liquid biopsy is being touted as a game changer in the cancer diagnostic and treatment market.

Market Insights

According to the latest research report by BIS Research, titled ‘Liquid Biopsy Market: 2017-2025’, the global liquid biopsy market is expected to grow at a CAGR of 22.5% from 2016 to 2025. The market is gaining pace due to the lack of medical procedures in the healthcare system for early detection and continuous monitoring of cancer patients, and the growing demand for non-invasive diagnostic procedures. However, some of the factors such as uncertain reimbursement and regulatory policies, lack of awareness, and high pricing pressure are restraining the growth of the market. Despite the restraints, liquid biopsy is gaining popularity among physicians due to its non-invasiveness, real time monitoring, and the ability to diagnose mutations in different organs with use of just one sample.

Liquid biopsy market comprises instruments, kits and consumables, and services by product types. Among these, kits and consumables segment dominated the global liquid biopsy market in 2016 and is expected to continue maintain its dominance by 2025. In addition to this, there are majorly two types of application of liquid biopsy, namely oncology and non-cancer applications. Between these two, oncology application dominates the market, and this trend will continue through 2025.

Geographically, North America held the largest market share in the global liquid biopsy market in 2016 owing to the high incidence rate of breast, and prostate cancer in the last five years. As a consequence, the liquid biopsy market in North America is dominated by the sales of prostate and breast cancer kits. The companies in this region are continuously working towards the expansion of this market by addressing this prevalent issue with numerous product offerings. The region that is expected to grow at the highest rate between 2016 and 2025 is Asia Pacific.

Some of the leading players in the market are:

  • Adaptive Biotechnologies
  • ANGLE plc
  • Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • Cynvenio Biosystems, Inc.
  • Epic Sciences
  • F. Hoffmann-La Roche AG
  • Genomic Health
  • Guardant Health
  • Illumina, Inc.


Stay up-to-date with the latest trending news stories and industry advances with the Research and Markets blog. Don’t forget to connect with us on LinkedIn and Twitter for the latest blog plus information about new products.

Published by Research and Markets


Liquid Biopsy Market: 2017-2025 - Product Image

Liquid Biopsy Market: 2017-2025

  • Report